EMA Reduces Parallel Distribution Fees For Malta & Latvia To Improve Medicines Availability
The European Medicines Agency is charging a reduced fee for parallel distribution of centrally authorized medicines to smaller EU member states under a new initiative that aims to improve the availability of medicines. Malta and Latvia have joined in, and two other member states have showed interest in the initiative, which will end in July 2018.
You may also be interested in...
Estonia and Slovenia have been accepted onto an ongoing initiative by the European Medicines Agency that aims to boost the availability of centrally authorized drugs in smaller member states by charging companies a reduced fee for parallel distribution of medicines.
The European Medicines Agency has launched a one-year pilot to help increase the availability of centrally authorized medicines in Malta by charging a reduced fee from companies involved in parallel distribution of medicines to the country1,2.
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.